Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;19(1):102429.
doi: 10.1016/j.autrev.2019.102429. Epub 2019 Nov 15.

Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies

José María G Ruiz de Morales  1 , Lluís Puig  2 , Esteban Daudén  3 , Juan D Cañete  4 , José Luis Pablos  5 , Antonio Olveira Martín  6 , Carlos González Juanatey  7 , Alfredo Adán  8 , Xavier Montalbán  9 , Natalia Borruel  10 , Guillermo Ortí  11 , Esther Holgado-Martín  12 , Carolina García-Vidal  13 , Cynthia Vizcaya-Morales  14 , Víctor Martín-Vázquez  15 , Miguel Ángel González-Gay  16
Affiliations
Free article
Review

Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies

José María G Ruiz de Morales et al. Autoimmun Rev. 2020 Jan.
Free article

Abstract

Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive research because of its crucial role in the pathogenesis of different diseases across many medical specialties. In this context, the present review in which a panel of 13 experts in immunology, dermatology, rheumatology, neurology, hematology, infectious diseases, hepatology, cardiology, ophthalmology and oncology have been involved, puts in common the mechanisms through which IL-17 is considered a molecular target for the development of novel biological therapies in these different fields. A comprehensive review of the literature and analysis of the most outstanding evidence have provided the basis for discussing the most relevant data related to IL-17A blocking agents for the treatment of different disorders, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, cardiovascular disorders, non alcoholic fatty liver disease, multiple sclerosis, inflammatory bowel disease, uveitis, hematological and solid cancer. Current controversies are presented giving an opening line for future research.

Keywords: Biological drugs; Citoquine; IL17A; Immunology; Inflammation; Psoriasis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

LinkOut - more resources